Yoshida Yoichiro, Aisu Naoya, Mogi Ai, Komono Akira, Sakamoto Ryohei, Kojima Daibo, Mera Toshiyuki, Hasegawa Suguru
aDepartment of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan.
bDivision of Oncology, Hematology and Infectious Diseases, Department of Internal Medicine, Fukuoka University Faculty of Medicine, Fukuoka, Japan.
Case Rep Oncol. 2017 Mar 2;10(1):226-229. doi: 10.1159/000460242. eCollection 2017 Jan-Apr.
TAS-102 significantly improves overall survival in patients with metastatic colorectal cancer. The most common adverse event of TAS-102 is bone marrow suppression, which leads to neutropenia. The incidence of neutropenia is high, and there is no known effective prevention method. Furthermore, the administration method of TAS-102 is complicated. We reported that neutropenia could be avoided by changing to a simple administration method of TAS-102.
TAS-102可显著提高转移性结直肠癌患者的总生存期。TAS-102最常见的不良事件是骨髓抑制，可导致中性粒细胞减少。中性粒细胞减少的发生率较高，且尚无已知的有效预防方法。此外，TAS-102的给药方法复杂。我们报告称，通过改用简单的TAS-102给药方法可避免中性粒细胞减少。
